GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...

The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...

In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...

The legal developments around ranitidine have been closely watched ... In other recent news, GlaxoSmithKline (NYSE:GSK) has reported notable developments. GSK's investigational biologic ...

GlaxoSmithKline didn't admit liability in ... involuntary recall of Zantac and other heartburn medications containing ranitidine, after discovering the presence of a possible carcinogen.

GlaxoSmithKline Pharmaceuticals Limited is ... In the year 1988, the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also, they started a joint venture project with ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...

GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according ...